PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Adcendo funding boosts antibody-drug conjugates development

Funds will be used to ensure the wider pan-sarcoma development of lead candidate uPARAP

Adcendo – a company that concentrates on the development of breakthrough antibody-drug conjugates (ADCs) for treating cancers with high unmet medical needs – has revealed that it has successfully completed vital funding.

The series A extension financing raised a further €31m, following the €51m series round two years ago. Funds will be used to ensure the broad pan-sarcoma development of lead ADC candidate uPARAP and further progress a second ADC asset.

The funding drive was led by Pontifax Venture Capital – a healthcare-focused venture capital firm – along with existing investors Ysios Capital and Novo Holdings. Meanwhile, other investors such as HealthCap, RA Capital Management and Gilde Healthcare also participated as the initiative yielded essential capital.

Under the terms of the agreement, Ohad Hammer, a partner at Pontifax Venture Capital, will join the Adcendo board of directors.

uPARAP is a novel cancer target overexpressed on the cell surface of sarcoma and other mesenchymal cancers. The expression profile and internalising properties of uPARAP make it an attractive ADC target. Indeed, uPARAP has shown a potential to be effective across multiple sarcoma subtypes.

Michael Pehl, chief executive officer at Adcendo, reflected: “This financing underscores the confidence that our investors have in Adcendo’s capabilities and potential to develop innovative ADC cancer therapies in high unmet medical need cancers. This financing will enable us to ensure a broad development programme of our lead asset uPARAP and further advance our second first-in-class ADC pipeline asset.”

Ohad Hammer, board director of Adcendo and partner at Pontifax Venture Capital, concluded: “We are excited to support Adcendo’s efforts to bring new treatments to patients with cancer as we continue our focus on seeking exciting transformative technologies to treat substantial unmet medical need indications.

“Adcendo’s ADC capabilities offer significant potential and I look forward to closely working with the team to develop their pipeline assets and bring innovative therapies to patients in need.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026